Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors10 April 2025Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer, today announces the appointment of Roger Dansey, M.D., a prominent leader in oncology research and drug development, to its board of directors. Read more
Ottimo Pharma Strengthens Leadership Team with Senior Appointments25 February 2025Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences, who will be leading Ottimo's preclinical programs and translational strategy, and Katherine Bell-McGuinn as Senior Vice President… Read more
Ottimo Pharma Raises over $140 Million in Series A Financing19 December 2024Ottimo Pharma (“Ottimo”), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today announces the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumor indications, in both IV and… Read more
